Clinical trial · Interventional
Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors
Biologic Evaluation of Renal Toxicity of Cisplatin and Ifosfamide (TOXIPLAT)
NCT00695032CI-TRIAL-00015990suspendedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is evaluating kidney damage in patients receiving cisplatin and ifosfamide for solid tumors.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapeutic Agent Toxicity | — | UNRESOLVED | — |
| Renal Toxicity | — | UNRESOLVED | — |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin | Drug | Cisplatin | ALIAS |
| ifosfamide | Drug | Ifosfamide | ALIAS |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Evolution of different biomarkers
- measure
- Sensitivity, specificity, and predictive value (positive and negative) of different markers
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of a solid tumor * Any location allowed * Metastatic disease allowed * Planned treatment comprising cisplatin and/or ifosfamide as standard chemotherapy PATIENT CHARACTERISTICS: Inclusion criteria: * Life expectancy \> 3 months * Creatinine clearance ≥ 60 mL/min * Must be available for follow up * Not pregnant or nursing * Not under guardianship or in prison Exclusion criteria: * Prior drug-related nephrotoxicity * Acute, uncontrolled urinary infection or \> 48-hours * Pre-existing hemorrhagic cystitis * Weak bladder * Bilateral obstruction of urinary tract * Insufficient, severe bone marrow hypoplasia * Cardiorespiratory condition contraindicating hyperhydration * Hearing impairment * Hypersensitivity to cisplatin or products containing platinum * Major psychiatric condition (severe depression, psychosis, dementia) PRIOR CONCURRENT THERAPY: * No prior yellow fever vaccine, live attenuated vaccine, or phenytoin * No concurrent participation in another biomedical study
References
Publications (0)
Data not yet available
No reference posted for this study.